1. Home
  2. BAFN vs ANL Comparison

BAFN vs ANL Comparison

Compare BAFN & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BayFirst Financial Corp.

BAFN

BayFirst Financial Corp.

N/A

Current Price

$7.90

Market Cap

40.6M

Sector

Finance

ML Signal

N/A

Logo Adlai Nortye Ltd.

ANL

Adlai Nortye Ltd.

HOLD

Current Price

$1.07

Market Cap

52.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
BAFN
ANL
Founded
1999
2004
Country
United States
Cayman Islands
Employees
N/A
N/A
Industry
Savings Institutions
Sector
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
40.6M
52.0M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
BAFN
ANL
Price
$7.90
$1.07
Analyst Decision
Hold
Analyst Count
0
1
Target Price
N/A
N/A
AVG Volume (30 Days)
5.6K
17.8K
Earning Date
01-29-2026
04-20-2026
Dividend Yield
2.02%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$58,931,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$6.40
$0.88
52 Week High
$19.75
$2.99

Technical Indicators

Market Signals
Indicator
BAFN
ANL
Relative Strength Index (RSI) 34.84 36.49
Support Level $8.05 $1.32
Resistance Level $8.07 $1.59
Average True Range (ATR) 0.08 0.18
MACD 0.04 -0.04
Stochastic Oscillator 0.00 31.12

Price Performance

Historical Comparison
BAFN
ANL

About BAFN BayFirst Financial Corp.

BayFirst Financial Corp is a bank holding company, it generates its revenue from interest on loans and the gain-on-sale income derived from the sale of loans into the secondary market. The company serves a broad spectrum of individuals, families, and small businesses, supported by national business lines in residential and SBA lending and technology platforms. The primary source of funding for its loans is deposits. BayFirst measures performance through net interest income after provision for loan losses, return on average assets, and return on average common equity, while maintaining appropriate regulatory leverage and risk-based capital ratios. The company has various segment such as Real Estate(Residential, Commercial, and Construction & Land), Commercial and Industrial, Consumer.

About ANL Adlai Nortye Ltd.

Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.

Share on Social Networks: